Core Viewpoint - The company plans to invest in a new biomanufacturing base for APIs and health dietary supplements in collaboration with the local government, aiming to enhance production efficiency and profitability [1] Investment Details - The total investment for the project is 420 million yuan, with approximately 300 million yuan allocated for fixed asset investment [1] - The land for the project will be provided by the local government, and the company will acquire the land use rights through market transactions or leasing [1] Project Construction - The project will involve the construction of production facilities and supporting infrastructure on newly purchased land in the Tokto Economic Development Zone [1] - Upon completion, the project is expected to help the company reduce production costs, expand profit margins, and improve its industrial chain layout [1] Strategic Benefits - The investment is anticipated to enhance the company's core profitability and sustainable development capabilities [1]

证券代码：301089 证券简称：拓新药业 公告编号：2025-067 拓新药业集团股份有限公司 关于全资子公司拟与托克托县人民政府签订项目投资协议 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、项目投资概述 拓新药业集团股份有限公司（以下简称"公司"）于 2025 年 12 月 2 日召开 的第五届董事会第九次会议审议通过了《关于全资子公司拟与托克托县人民政府 签订项目投资协议的议案》。公司子公司拓新药业（内蒙古）有限公司（以下简 称"乙方"）拟与内蒙古自治区托克托县人民政府（以下简称"甲方"）签署《内 蒙古自治区托克托县拓新药业（内蒙古）有限公司原料药及健康膳食补充剂生物 制造基地建设项目投资协议》。 本次拟投资协议不构成关联交易，也不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。根据《深圳证券交易所创业板股票上市规则》《公司 章程》等相关规定，该事项在公司董事会决策权限范围内，无需提交公司股东会 审议。 二、交易对方的基本情况 建设规模：项目总投资为 4.2 亿元，其中固定资产投资 3 亿元左右 本次交易的交易对方为内蒙古自治 ...

Core Viewpoint - The A-share market experienced a significant rally on November 25, with the ChiNext Index rising nearly 2%, driven by a surge in flu-related stocks due to an increase in flu activity across the country [1] Group 1: Market Performance - The ChiNext Index saw a nearly 2% increase on November 25, indicating strong market performance [1] - Flu-related stocks, such as Jindike and Xinhua Pharmaceutical, reached their daily limit up, reflecting heightened investor interest [1] Group 2: Flu Activity and Sales Data - National flu activity has rapidly increased in November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Sales of Oseltamivir surged by 237% over the past week, while sales of Maviral (Sofosbuvir) increased by 180% [1] - Data from Meituan indicates that special flu medications in Beijing have seen a month-on-month growth exceeding 130%, with Maviral growing over 110% and Oseltamivir granules increasing by over 85% [1] Group 3: Investment Opportunities - According to Everbright Securities, the rising flu epidemic is likely to increase public and market attention, leading to a growth in demand for flu prevention and treatment products [1] - Investment opportunities are suggested in flu vaccines, virus testing, cold medications, and special antiviral drugs, as well as blood products as a response to complex epidemic situations [1]

证券日报网讯拓新药业（301089）11月24日在互动平台回答投资者提问时表示，截至2025年11月20日， 公司股东户数19047户。 ...

Core Viewpoint - Recently, Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. was established with a registered capital of 50 million yuan, indicating the company's expansion into various sectors including food additives and pharmaceuticals [1] Company Summary - Tuoxin Pharmaceutical has a registered capital of 50 million yuan [1] - The company's business scope includes the production of food additives, pharmaceuticals, health food, and food sales, as well as the import and export of pharmaceuticals [1] - Tuoxin Pharmaceutical is wholly owned by Tuoxin Pharmaceutical, reflecting a consolidated ownership structure [1]

Core Viewpoint - The company announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd., has obtained the FSSC 22000 certification for food safety management from the internationally recognized certification body Intertek [2] Group 1 - The certification signifies compliance with international food safety standards, enhancing the company's credibility in the biotechnology sector [2] - This achievement may open new market opportunities for the company, particularly in food safety and quality assurance [2] - The certification process reflects the company's commitment to maintaining high standards in its operations and products [2]

Core Points - The company announced the convening of the second extraordinary general meeting of shareholders for 2025 on November 13, 2025, to review the proposal regarding the resignation of independent directors and the election of new independent directors [2] - The company approved the election of Dong Hongjie and Yang Dejie as independent directors of the fifth board of directors [2] - Dong Hongjie has completed the required training for independent directors organized by the Shenzhen Stock Exchange and received the training certificate [2]

Core Points - The company announced the establishment of a wholly-owned subsidiary, Tuoxin Pharmaceutical (Inner Mongolia) Co., Ltd. [2] - The board meeting to approve the investment in the subsidiary was held on October 28, 2025 [2] - The subsidiary has completed its business registration and obtained a business license from the Hohhot Tokto Economic Development Zone Management Committee [2]

Core Viewpoint - The company, Tuoxin Pharmaceutical (301089.SZ), announced that its wholly-owned subsidiary, Xinxiang Jingquan Biotechnology Co., Ltd. (referred to as "Jingquan Bio"), has obtained the FSSC 22000 certification from the internationally recognized certification body Intertek, enhancing its foundation in food safety and management in functional food production [1] Group 1 - The certification ensures that the company's products strictly adhere to food safety production standards, effectively mitigating food safety risks [1] - The successful acquisition of this certification will provide strong support for the company's product expansion in domestic and international markets [1] - This achievement is expected to enhance the company's overall market competitiveness, creating broader development space and better operational efficiency [1]

Core Viewpoint - The company has successfully obtained the FSSC 22000 certification for food safety, enhancing its credibility in functional food production and management [1] Group 1: Certification Details - The certification was issued by the internationally recognized certification body Intertek [1] - The certificate number is 162411011, and it is valid until November 12, 2027 [1] Group 2: Impact on Business - The certification strengthens the company's foundation in food safety and management, ensuring strict adherence to food safety production standards [1] - This achievement will support the company's efforts to expand its products in both domestic and international markets [1] - It is expected to enhance the company's overall market competitiveness and create broader development opportunities and better operational efficiency [1]